<DOC>
	<DOCNO>NCT00485472</DOCNO>
	<brief_summary>The purpose trial evaluate effectiveness , safety tolerability lacosamide ( LCM ) 400mg/day treat sign symptom osteoarthritis knee .</brief_summary>
	<brief_title>Trial Assess Efficacy Safety Lacosamide Subjects With Osteoarthritis Knee</brief_title>
	<detailed_description>LCM investigational drug study treatment male female patient diagnose osteoarthritis knee require therapeutic dos NSAIDs , COX-2 NSAIDs and/or paracetamol . This trial conduct exclusively Europe . The study adaptive 3-stage group sequential design . The trial last total 17 week . There 2 week period wean current medication , follow 4 week period patient receive placebo ( inactive drug ) gradually increase dos LCM target dose 400mg/day . The target dose placebo maintain 8 week follow 1 week reduction period 2 week safety follow period . The last subject expect enrolled December 2007 . The study terminate base outcome plan first interim analysis , perform define protocol subset patient . It decide continue trial . No safety concern identify .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subject symptomatic osteoarthritis knee diagnose use clinical radiographic evidence well ACR criterion symptom duration least 6 month . Subject require therapeutic dose NSAID , COX2 NSAID , and/or paracetamol/acetaminophen osteoarthritis pain index knee take medication least 5 day per week last 4 week prior screen visit ( Visit 1 ) . Subject able withdraw NSAIDs , COX2 NSAIDs and/or paracetamol Subject take analgesic NSAIDs COX2 NSAIDs and/or paracetamol Subject planning begin stop treatment glucosamine and/or chondroitin trial</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>lacosamide</keyword>
	<keyword>VIMPAT</keyword>
</DOC>